

# Helen Philippou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6797516/publications.pdf>

Version: 2024-02-01

46  
papers

2,328  
citations

279701

23  
h-index

254106

43  
g-index

47  
all docs

47  
docs citations

47  
times ranked

2487  
citing authors

#	ARTICLE	IF	CITATIONS
1	The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. <i>Blood</i> , 2000, 96, 988-995.	0.6	314
2	Directing thrombin. <i>Blood</i> , 2005, 106, 2605-2612.	0.6	298
3	Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. <i>Blood</i> , 2010, 115, 3980-3988.	0.6	143
4	The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 197-205.	1.9	136
5	Factor V Leiden Gene Mutation and Thrombin Generation in Relation to the Development of Acute Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 783-785.	1.1	119
6	Factor XIIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. <i>Blood</i> , 2011, 118, 3942-3951.	0.6	114
7	Immobilized fibrinogen activates human platelets through glycoprotein VI. <i>Haematologica</i> , 2018, 103, 898-907.	1.7	101
8	The pleiotropic role of the fibrinogen $\beta$ chain in hemostasis. <i>Blood</i> , 2009, 114, 3994-4001.	0.6	91
9	A fibrin biofilm covers blood clots and protects from microbial invasion. <i>Journal of Clinical Investigation</i> , 2018, 128, 3356-3368.	3.9	88
10	Clot properties and cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 901-908.	1.8	80
11	Fibrin and D-dimer bind to monomeric GPVI. <i>Blood Advances</i> , 2017, 1, 1495-1504.	2.5	72
12	Roles of fibrin $\alpha$ - and $\beta$ -chain specific cross-linking by FXIIIa in fibrin structure and function. <i>Thrombosis and Haemostasis</i> , 2014, 112, 842-850.	1.8	69
13	Role of Fibrin Structure in Thrombosis and Vascular Disease. <i>Advances in Protein Chemistry and Structural Biology</i> , 2011, 83, 75-127.	1.0	68
14	Interactions between factor XIII and the $\alpha$ C region of fibrinogen. <i>Blood</i> , 2011, 117, 3460-3468.	0.6	56
15	Clot Architecture Is Altered in Abdominal Aortic Aneurysms and Correlates With Aneurysm Size. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 3004-3010.	1.1	55
16	Thrombin and fibrinogen $\beta$ impact clot structure by marked effects on intrafibrillar structure and protofibril packing. <i>Blood</i> , 2016, 127, 487-495.	0.6	53
17	Structure functional insights into calcium binding during the activation of coagulation factor XIII A. <i>Scientific Reports</i> , 2019, 9, 11324.	1.6	52
18	The interaction between fibrinogen and zymogen FXIII-A2B2 is mediated by fibrinogen residues $\beta$ 390-396 and the FXIII-B subunits. <i>Blood</i> , 2016, 128, 1969-1978.	0.6	42

#	ARTICLE	IF	CITATIONS
19	Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
20	Roles of Low Specificity and Cofactor Interaction Sites on Thrombin during Factor XIII Activation. Journal of Biological Chemistry, 2003, 278, 32020-32026.	1.6	37
21	The role of activated coagulation factor XII in overall clot stability and fibrinolysis. Thrombosis Research, 2015, 136, 474-480.	0.8	33
22	The activation peptide cleft exposed by thrombin cleavage of FXIII-A2 contains a recognition site for the fibrinogen I $\pm$ chain. Blood, 2013, 121, 2117-2126.	0.6	31
23	Revisiting the mechanism of coagulation factor XIII activation and regulation from a structure/functional perspective. Scientific Reports, 2016, 6, 30105.	1.6	28
24	Factor XIII A-Subunit V34L Variant Affects Thrombus Cross-Linking in a Murine Model of Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 308-316.	1.1	23
25	Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. Blood, 2011, 117, 6694-6701.	0.6	19
26	Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis. Platelets, 2019, 30, 893-900.	1.1	19
27	Coagulation Factor XIII A Subunit Missense Mutations Affect Structure and Function at the Various Steps of Factor XIII Action. Human Mutation, 2016, 37, 1030-1041.	1.1	17
28	Fibrin clot structure remains unaffected in young, healthy individuals after transient exposure to diesel exhaust. Particle and Fibre Toxicology, 2010, 7, 17.	2.8	16
29	Ranking reactive glutamines in the fibrinogen I $\pm$ C region that are targeted by blood coagulant factor XIII. Blood, 2016, 127, 2241-2248.	0.6	13
30	Fibrinogen I $\pm$ C-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis. ELife, 2021, 10, .	2.8	13
31	Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1269-1281.	1.0	12
32	Partial deletion of the I $\pm$ C-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis. Thrombosis and Haemostasis, 2013, 110, 1135-1144.	1.8	11
33	The alpha-2-antiplasmin Arg407Lys polymorphism is associated with Abdominal Aortic Aneurysm. Thrombosis Research, 2014, 134, 723-728.	0.8	10
34	Proteolytic and nonproteolytic activation mechanisms result in conformationally and functionally different forms of coagulation factor XIII A. FEBS Journal, 2020, 287, 452-464.	2.2	10
35	Elimination of fibrin I $\beta$ -chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2103226118.	3.3	10
36	Altered fibrin clot structure in patients with atrial fibrillation and worsening renal function. Thrombosis and Haemostasis, 2016, 116, 408-409.	1.8	8

#	ARTICLE	IF	CITATIONS
37	Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1057-1069.	1.9	8
38	The role of $\beta$ -barrels 1 and 2 in the enzymatic activity of factor XIII A-subunit. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1391-1401.	1.9	6
39	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12213-12242.	2.9	5
40	A Comparative Assessment Study of Known Small-molecule GPVI Modulators. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 171-181.	1.3	4
41	Novel interaction of properdin and coagulation factor XI: Crosstalk between complement and coagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12715.	1.0	4
42	Unexplained bleeding: another player to look out for!. <i>Blood</i> , 2014, 124, 1850-1851.	0.6	1
43	Observations on clot properties in atrial fibrillation: Relation to renal function and choice of anticoagulant. <i>Thrombosis Research</i> , 2021, 197, 69-76.	0.8	1
44	FXII inhibition: multipronged benefits. <i>Blood</i> , 2021, 138, 107-109.	0.6	0
45	Investigating the functional relationship between streptokinase variants from Group A <i>Streptococcus</i> , and associated M-like proteins. <i>Access Microbiology</i> , 2020, 2, .	0.2	0
46	Investigating the impact of M1 protein from Group A <i>Streptococcus</i> on fibrin clot formation, structure and fibrinolytic potential. <i>Access Microbiology</i> , 2020, 2, .	0.2	0